SecSonar.com

Heron Therapeutics, Inc. (HRTX)

Heron Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Heron Therapeutics, Inc. (HRTX) is a Biotechnology company based in US with a market capitalization of $135.1M. Revenue grew 7.4% year-over-year and free cash flow was negative at -$27.9M. This page tracks HRTX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 122 employees · IPO Aug 26, 1987

Valuation

Valuation & price

$0.85 · as of May 17, 2026 · -61.9% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

9.43

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$2.23$1.31$0.39Jul 25Dec 25Jul 26Jul 7, 25$2.15Jul 9, 25$2.23Jul 11, 25$2.18Jul 15, 25$2.04Jul 17, 25$2.00Jul 21, 25$1.92Jul 23, 25$1.96Jul 25, 25$1.91Jul 29, 25$1.85Jul 31, 25$1.73Aug 4, 25$1.75Aug 6, 25$1.81Aug 11, 25$1.28Aug 13, 25$1.40Aug 15, 25$1.33Aug 19, 25$1.29Aug 21, 25$1.32Aug 25, 25$1.38Aug 27, 25$1.36Aug 29, 25$1.35Sep 3, 25$1.33Sep 5, 25$1.31Sep 9, 25$1.30Sep 11, 25$1.28Sep 16, 25$1.24Sep 18, 25$1.29Sep 22, 25$1.30Sep 24, 25$1.25Sep 26, 25$1.21Sep 30, 25$1.26Oct 2, 25$1.30Oct 6, 25$1.34Oct 8, 25$1.35Oct 10, 25$1.28Oct 14, 25$1.32Oct 16, 25$1.30Oct 21, 25$1.30Oct 23, 25$1.19Oct 27, 25$1.18Oct 29, 25$1.17Oct 31, 25$1.16Nov 4, 25$1.14Nov 6, 25$1.10Nov 10, 25$1.11Nov 12, 25$1.11Nov 14, 25$1.10Nov 18, 25$1.12Nov 20, 25$1.06Nov 25, 25$1.09Nov 28, 25$1.16Dec 2, 25$1.17Dec 4, 25$1.31Dec 8, 25$1.35Dec 10, 25$1.37Dec 12, 25$1.37Dec 16, 25$1.38Dec 18, 25$1.29Dec 22, 25$1.34Dec 24, 25$1.28Dec 29, 25$1.31Jan 2, 26$1.26Jan 6, 26$1.22Jan 8, 26$1.27Jan 12, 26$1.49Jan 14, 26$1.49Jan 16, 26$1.49Jan 21, 26$1.46Jan 23, 26$1.42Jan 27, 26$1.40Jan 29, 26$1.34Feb 2, 26$1.38Feb 4, 26$1.32Feb 9, 26$1.28Feb 11, 26$1.17Feb 13, 26$1.15Feb 18, 26$1.21Feb 20, 26$1.18Feb 24, 26$1.09Feb 26, 26$1.20Mar 2, 26$1.20Mar 4, 26$1.13Mar 6, 26$0.97Mar 10, 26$0.99Mar 12, 26$0.93Mar 17, 26$0.87Mar 19, 26$0.82Mar 23, 26$0.80Mar 25, 26$0.80Mar 27, 26$0.78Mar 31, 26$0.80Apr 2, 26$0.80Apr 7, 26$0.79Apr 9, 26$0.82Apr 13, 26$0.91Apr 15, 26$0.96Apr 17, 26$1.00Apr 22, 26$1.02Apr 24, 26$1.19Apr 28, 26$1.21Apr 30, 26$1.20May 4, 26$1.22May 6, 26$1.31May 8, 26$1.21May 12, 26$0.96May 14, 26$0.91May 18, 26$0.86May 20, 26$0.85May 22, 26$0.86May 28, 26$0.89Jun 1, 26$0.83Jun 3, 26$0.45Jun 5, 26$0.43Jun 9, 26$0.40Jun 11, 26$0.41Jun 15, 26$0.40Jun 17, 26$0.39Jun 22, 26$0.43Jun 24, 26$0.43Jun 26, 26$0.43Jul 2, 26$0.44
$0.3852-week range$2.23
Loading valuation history…

Fundamentals

Key fundamentals

$135.1M

Market cap

7.4%

Revenue growth (YoY)

73.3%

Gross margin

-$27.9M

Free cash flow (USD)

$94M

Net debt

9.3%

Share dilution

0/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$1.3MFY 2017$30.8MFY 2018$77.5MFY 2019$146.0MFY 2020$88.6MFY 2021$86.3MFY 2022$107.7MFY 2023$127.0MFY 2024$144.3MFY 2025$154.9M
$1.3M$154.9M

Free cash flow by year

2016 → 2025

FY 2016$-137.2MFY 2017$-172.9MFY 2018$-201.0MFY 2019$-131.7MFY 2020$-191.6MFY 2021$-206.4MFY 2022$-148.7MFY 2023$-60.3MFY 2024$-24.2MFY 2025$-27.9M
-$137.2M-$27.9M

Gross margin by year

2021 → 2025

FY 202146.7%FY 202249.0%FY 202348.8%FY 202473.2%FY 202573.3%
46.7%73.3%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 11, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventDelisting NoticeJun 25, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 16, 2026Filing
  • 8-K eventPatent RulingJun 2, 2026Filing
  • 8-K eventEarnings ReleaseMay 11, 2026Filing
  • Quarterly report10-Q FiledMay 11, 2026Filing
  • 8-K eventExecutive Employment Agreement AmendedApr 6, 2026Filing

Questions

Frequently asked questions

What is Heron Therapeutics, Inc.'s market cap?

Heron Therapeutics, Inc. (HRTX) has a market capitalization of $135.1M.

What is HRTX's P/E ratio?

A meaningful P/E ratio is not available for HRTX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is HRTX's price-to-book (P/B) ratio?

HRTX trades at 9.43 times book value per share.

Are insiders buying HRTX stock?

SEC Form 4 filings show no open-market insider buys at Heron Therapeutics, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

QTTB

Q32 Bio Inc.

$137.6M

AGEN

Agenus Inc.

$139.1M

BDTX

Black Diamond Therapeutics, Inc.

$130.1M

KRRO

Korro Bio, Inc.

$129.6M

IKT

Inhibikase Therapeutics, Inc.

$125.3M

CRDF

Cardiff Oncology, Inc.

$124.8M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.